{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:36:35Z","timestamp":1792046195275,"version":"4.4.0"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.pharep.2014.09.004","type":"journal-article","created":{"date-parts":[[2014,9,21]],"date-time":"2014-09-21T22:04:20Z","timestamp":1411337060000},"page":"195-203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1389,"title":["A review on Alzheimer's disease pathophysiology and its management: an update"],"prefix":"10.1007","volume":"67","author":[{"given":"Anil","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arti","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ekavali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"10.1016\/j.pharep.2014.09.004_bib0005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.neuropharm.2013.07.004","article-title":"Therapeutics of Alzheimer's disease: past, present and future","volume":"76","author":"Anand","year":"2014","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.pharep.2014.09.004_bib0010","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jalz.2014.02.001","article-title":"Alzheimer's disease facts and figures","volume":"10","author":"Alzheimer's Association","year":"2014","journal-title":"Alzheimers Dement"},{"issue":"8","key":"10.1016\/j.pharep.2014.09.004_bib0015","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.arcmed.2012.11.008","article-title":"Alzheimer's disease: critical notes on the history of a medical concept","volume":"43","author":"Ramirez-Bermudez","year":"2012","journal-title":"Arch Med Res"},{"issue":"3","key":"10.1016\/j.pharep.2014.09.004_bib0020","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0301-0082(02)00079-5","article-title":"Alzheimer's disease and the basal forebrain cholinergic system: relations to \u03b2-amyloid peptides, cognition, and treatment strategies","volume":"68","author":"Auld","year":"2002","journal-title":"Prog Neurobiol"},{"issue":"5","key":"10.1016\/j.pharep.2014.09.004_bib0025","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1159\/000122962","article-title":"Treatment options in Alzheimer's disease: maximizing benefit, managing expectations","volume":"25","author":"Farlow","year":"2008","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"2","key":"10.1016\/j.pharep.2014.09.004_bib0030","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.pnpbp.2010.07.018","article-title":"Novel insights for the treatment of Alzheimer's disease","volume":"35","author":"Kurz","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"5","key":"10.1016\/j.pharep.2014.09.004_bib0035","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1358\/dof.2008.033.05.1192677","article-title":"Neuropathology and therapeutic management of Alzheimer's disease \u2013 an update","volume":"33","author":"Kumar","year":"2008","journal-title":"Drugs Future"},{"issue":"4","key":"10.1016\/j.pharep.2014.09.004_bib0040","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/j.1471-4159.2009.06181.x","article-title":"The amyloid hypothesis for Alzheimer's disease: a critical reappraisal","volume":"110","author":"Hardy","year":"2009","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharep.2014.09.004_bib0045","article-title":"Do astrocytes collaborate with neurons in spreading the \u201cinfectious\u201d A\u03b2 and tau drivers of Alzheimer's disease?","author":"Dal Pr\u00e0","year":"2014","journal-title":"Neuroscientist"},{"issue":"4","key":"10.1016\/j.pharep.2014.09.004_bib0050","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1365-2125.2011.04134.x","article-title":"New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs","volume":"73","author":"Salomone","year":"2012","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.pharep.2014.09.004_bib0055","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2174\/1567205011310030001","article-title":"Immunotherapy for targeting tau pathology in Alzheimers disease and tauopathies","volume":"10","author":"Rosenmann","year":"2013","journal-title":"Curr Alzheimer Res"},{"issue":"3","key":"10.1016\/j.pharep.2014.09.004_bib0060","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/107385849800400310","article-title":"A theory of cortical neuron\u2013astrocyte interaction","volume":"4","author":"Antanitus","year":"1998","journal-title":"Neuroscientist"},{"issue":"4","key":"10.1016\/j.pharep.2014.09.004_bib0065","doi-asserted-by":"crossref","first-page":"381","DOI":"10.4067\/S0716-97602005000400011","article-title":"Oligodendrocytes damage in Alzheimer's disease: beta amyloid toxicity and inflammation","volume":"38","author":"Roth","year":"2005","journal-title":"Biol Res"},{"issue":"1","key":"10.1016\/j.pharep.2014.09.004_bib0070","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jns.2012.12.013","article-title":"Immunotherapy against amyloid pathology in Alzheimer's disease","volume":"333","author":"Galimberti","year":"2013","journal-title":"J Neurol Sci"},{"issue":"3","key":"10.1016\/j.pharep.2014.09.004_bib0075","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1046\/j.1471-4159.2003.01552.x","article-title":"Cholesterol is necessary both for the toxic effect of A\u03b2 peptides on vascular smooth muscle cells and for A\u03b2 binding to vascular smooth muscle cell membranes","volume":"84","author":"Subasinghe","year":"2003","journal-title":"J Neurochem"},{"issue":"1","key":"10.1016\/j.pharep.2014.09.004_bib0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2012.02.002","article-title":"Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease","volume":"97","author":"Xu","year":"2012","journal-title":"Prog Neurobiol"},{"issue":"1","key":"10.1016\/j.pharep.2014.09.004_bib0085","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/ijmm.2012.1162","article-title":"Alzheimer's disease: an update of the roles of receptors, astrocytes and primary cilia","volume":"31","author":"Armato","year":"2013","journal-title":"Int J Mol Med"},{"issue":"1","key":"10.1016\/j.pharep.2014.09.004_bib0090","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0006-8993(01)03008-6","article-title":"Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain","volume":"919","author":"Yasojima","year":"2001","journal-title":"Brain Res"},{"issue":"5","key":"10.1016\/j.pharep.2014.09.004_bib0095","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00401-011-0825-z","article-title":"Alzheimer's pathogenesis: is there neuron-to-neuron propagation?","volume":"121","author":"Braak","year":"2011","journal-title":"Acta Neuropathol"},{"issue":"2","key":"10.1016\/j.pharep.2014.09.004_bib0100","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.biocel.2004.07.009","article-title":"The role of inflammation in Alzheimer's disease","volume":"37","author":"Tuppo","year":"2005","journal-title":"Int J Biochem Cell Biol"},{"issue":"6006","key":"10.1016\/j.pharep.2014.09.004_bib0105","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1126\/science.1194516","article-title":"Peripherally applied A\u03b2-containing inoculates induce cerebral \u03b2-amyloidosis","volume":"330","author":"Eisele","year":"2010","journal-title":"Science"},{"issue":"27","key":"10.1016\/j.pharep.2014.09.004_bib0110","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1073\/pnas.1306832110","article-title":"A\u03b2 induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss","volume":"110","author":"Talantova","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.pharep.2014.09.004_bib0115","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.mad.2005.09.018","article-title":"Treatment of Alzheimer's disease: from pharmacology to a better understanding of disease pathophysiology","volume":"127","author":"Silvestrelli","year":"2006","journal-title":"Mech Ageing Dev"},{"issue":"6740","key":"10.1016\/j.pharep.2014.09.004_bib0120","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-\u03b2 attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pharep.2014.09.004_bib0125","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1471-4159.2004.02385.x","article-title":"Clearing amyloid through the blood\u2013brain barrier","volume":"89","author":"Zlokovic","year":"2004","journal-title":"J Neurochem"},{"issue":"9","key":"10.1016\/j.pharep.2014.09.004_bib0130","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/nm1635","article-title":"Clearance of amyloid-\u03b2 by circulating lipoprotein receptors","volume":"13","author":"Sagare","year":"2007","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.pharep.2014.09.004_bib0135","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3233\/JAD-2009-1030","article-title":"RAGE and Alzheimer's disease: a progression factor for amyloid-\u03b2-induced cellular perturbation?","volume":"16","author":"Yan","year":"2009","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.pharep.2014.09.004_bib0140","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1471-4159.2011.07476.x","article-title":"Developing \u03b2-secretase inhibitors for treatment of Alzheimer's disease","volume":"120","author":"Ghosh","year":"2012","journal-title":"J Neurochem"},{"issue":"2","key":"10.1016\/j.pharep.2014.09.004_bib0145","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1096\/fj.10-167213","article-title":"\u03b2-Secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice","volume":"25","author":"Chang","year":"2011","journal-title":"FASEB J"},{"issue":"1","key":"10.1016\/j.pharep.2014.09.004_bib0150","doi-asserted-by":"crossref","first-page":"102","DOI":"10.5114\/aoms.2011.20612","article-title":"Tramiprosate in mild-to-moderate Alzheimer's disease \u2013 a randomized, double-blind, placebo-controlled, multi-centre study (the Al phase Study)","volume":"7","author":"Aisen","year":"2011","journal-title":"Arch Med Sci"},{"issue":"4","key":"10.1016\/j.pharep.2014.09.004_bib0155","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jalz.2009.04.950","article-title":"Scyllo-inositol (ELND005) ameliorates amyloid pathology in an aggressive mouse model of Alzheimer's disease","volume":"5","author":"DaSilva","year":"2009","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.1016\/j.pharep.2014.09.004_bib0160","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2174\/156720510791162377","article-title":"Colostral proline-rich polypeptides \u2013 immunoregulatory properties and prospects of therapeutic use in Alzheimers disease","volume":"7","author":"Janusz","year":"2010","journal-title":"Curr Alzheimer Res"},{"issue":"25","key":"10.1016\/j.pharep.2014.09.004_bib0165","doi-asserted-by":"crossref","first-page":"8754","DOI":"10.1073\/pnas.0710823105","article-title":"Enhanced clearance of A\u03b2 in brain by sustaining the plasmin proteolysis cascade","volume":"105","author":"Jacobsen","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.pharep.2014.09.004_bib0170","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/nm1206","article-title":"Somatostatin regulates brain amyloid \u03b2 peptide A\u03b242 through modulation of proteolytic degradation","volume":"11","author":"Saito","year":"2005","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.pharep.2014.09.004_bib0175","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3233\/JAD-2011-110134","article-title":"Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial","volume":"26","author":"Scarpini","year":"2011","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"10.1016\/j.pharep.2014.09.004_bib0180","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000090368","article-title":"Clinical observations with AN-1792 using TAPIR analyses","volume":"2","author":"Hock","year":"2006","journal-title":"Neurodegener Dis"},{"issue":"4","key":"10.1016\/j.pharep.2014.09.004_bib0185","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nm840","article-title":"Neuropathology of human Alzheimer disease after immunization with amyloid-\u03b2 peptide: a case report","volume":"9","author":"Nicoll","year":"2003","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.pharep.2014.09.004_bib0190","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0165-0173(00)00019-9","article-title":"Tau protein isoforms, phosphorylation and role in neurodegenerative disorders","volume":"33","author":"Bu\u00e9e","year":"2000","journal-title":"Brain Res Rev"},{"issue":"6","key":"10.1016\/j.pharep.2014.09.004_bib0195","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1111\/j.1471-4159.2006.04139.x","article-title":"Chronic lithium administration to FTDP-17 tau and GSK-3\u03b2 overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert","volume":"99","author":"Engel","year":"2006","journal-title":"J Neurochem"},{"issue":"1","key":"10.1016\/j.pharep.2014.09.004_bib0200","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1073\/pnas.0406361102","article-title":"Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model","volume":"102","author":"Zhang","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"41","key":"10.1016\/j.pharep.2014.09.004_bib0205","doi-asserted-by":"crossref","first-page":"13861","DOI":"10.1523\/JNEUROSCI.3059-10.2010","article-title":"Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy","volume":"30","author":"Brunden","year":"2010","journal-title":"J Neurosci"},{"issue":"10","key":"10.1016\/j.pharep.2014.09.004_bib0210","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.2174\/138161211795589373","article-title":"NAP (davunetide) provides functional and structural neuroprotection","volume":"17","author":"Gozes","year":"2011","journal-title":"Curr Pharm Des"},{"issue":"3","key":"10.1016\/j.pharep.2014.09.004_bib0215","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1096\/fj.07-9610com","article-title":"Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways","volume":"22","author":"Atamna","year":"2008","journal-title":"FASEB J"},{"issue":"2","key":"10.1016\/j.pharep.2014.09.004_bib0220","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3233\/JAD-2010-1262","article-title":"Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease","volume":"19","author":"Rojo","year":"2010","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"10.1016\/j.pharep.2014.09.004_bib0225","doi-asserted-by":"crossref","first-page":"609","DOI":"10.4161\/auto.19048","article-title":"Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo","volume":"8","author":"Congdon","year":"2012","journal-title":"Autophagy"},{"issue":"1","key":"10.1016\/j.pharep.2014.09.004_bib0230","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/sj.bjp.0701355","article-title":"The interaction between methylene blue and the cholinergic system","volume":"122","author":"Pfaffendorf","year":"1997","journal-title":"Br J Pharmacol"},{"issue":"6","key":"10.1016\/j.pharep.2014.09.004_bib0235","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s00018-009-0233-x","article-title":"The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition","volume":"67","author":"Giommarelli","year":"2010","journal-title":"Cell Mol Life Sci"},{"issue":"6","key":"10.1016\/j.pharep.2014.09.004_bib0240","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1074\/jbc.M112.393751","article-title":"Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice","volume":"288","author":"Ma","year":"2013","journal-title":"J Biol Chem"},{"issue":"39","key":"10.1016\/j.pharep.2014.09.004_bib0245","doi-asserted-by":"crossref","first-page":"34457","DOI":"10.1074\/jbc.M111.229633","article-title":"Passive immunization with anti-tau antibodies in two transgenic models reduction of tau pathology and delay of disease progression","volume":"286","author":"Chai","year":"2011","journal-title":"J Biol Chem"},{"issue":"25","key":"10.1016\/j.pharep.2014.09.004_bib0250","doi-asserted-by":"crossref","first-page":"8075","DOI":"10.1523\/JNEUROSCI.0864-09.2009","article-title":"Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-\u03b2 load in an Alzheimer's disease mouse model","volume":"29","author":"Puzzo","year":"2009","journal-title":"J Neurosci"},{"issue":"2","key":"10.1016\/j.pharep.2014.09.004_bib0255","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00213-010-1943-3","article-title":"Inhibition of phosphodiesterase-4 reverses memory deficits produced by A\u03b225\u201335 or A\u03b21\u201340 peptide in rats","volume":"212","author":"Cheng","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"10.1016\/j.pharep.2014.09.004_bib0260","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bbrc.2011.04.068","article-title":"Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid beta-induced cognitive deficits associated with decreased amyloid beta accumulation","volume":"408","author":"Park","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/j.pharep.2014.09.004_bib0265","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3233\/JAD-2012-121537","article-title":"Cognitive enhancers (nootropics). Part 2: Drugs interacting with enzymes","volume":"33","author":"Froestl","year":"2013","journal-title":"J Alzheimers Dis"},{"issue":"9","key":"10.1016\/j.pharep.2014.09.004_bib0270","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s00702-011-0619-4","article-title":"Inhibition of phospholipase A2 in rat brain decreases the levels of total tau protein","volume":"118","author":"Schaeffer","year":"2011","journal-title":"J Neural Transm"},{"issue":"49","key":"10.1016\/j.pharep.2014.09.004_bib0275","doi-asserted-by":"crossref","first-page":"16419","DOI":"10.1523\/JNEUROSCI.3317-10.2010","article-title":"Phospholipase d2 ablation ameliorates Alzheimer's disease-linked synaptic dysfunction and cognitive deficits","volume":"30","author":"Oliveira","year":"2010","journal-title":"J Neurosci"},{"issue":"13","key":"10.1016\/j.pharep.2014.09.004_bib0280","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1001\/jama.1994.03510370044030","article-title":"Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease","volume":"271","author":"Watkins","year":"1994","journal-title":"JAMA"},{"issue":"1\u20132","key":"10.1016\/j.pharep.2014.09.004_bib0285","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12031-009-9269-5","article-title":"Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy","volume":"40","author":"Maelicke","year":"2010","journal-title":"J Mol Neurosci"},{"issue":"2","key":"10.1016\/j.pharep.2014.09.004_bib0290","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10571-007-9163-z","article-title":"Non-cholinergic effects of huperzine A: beyond inhibition of acetylcholinesterase","volume":"28","author":"Zhang","year":"2008","journal-title":"Cell Mol Neurobiol"},{"issue":"1","key":"10.1016\/j.pharep.2014.09.004_bib0295","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1471-4159.2011.07507.x","article-title":"Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease","volume":"120","author":"Fisher","year":"2012","journal-title":"J Neurochem"},{"issue":"5","key":"10.1016\/j.pharep.2014.09.004_bib0300","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1517\/13543776.2013.769522","article-title":"Sigma receptor modulators: a patent review","volume":"23","author":"Collina","year":"2013","journal-title":"Expert Opin Ther Pat"},{"issue":"7","key":"10.1016\/j.pharep.2014.09.004_bib0305","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1755-5949.2012.00317.x","article-title":"Cotinine: a potential new therapeutic agent against Alzheimer's disease","volume":"18","author":"Echeverria","year":"2012","journal-title":"CNS Neurosci Ther"},{"issue":"4","key":"10.1016\/j.pharep.2014.09.004_bib0310","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/j.1471-4159.2007.04832.x","article-title":"GABAA receptors in aging and Alzheimer's disease","volume":"103","author":"Rissman","year":"2007","journal-title":"J Neurochem"},{"issue":"2","key":"10.1016\/j.pharep.2014.09.004_bib0315","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4155\/fmc.10.291","article-title":"GABAergic drugs and Alzheimer's disease","volume":"3","author":"Limon","year":"2011","journal-title":"Future Med Chem"},{"issue":"1","key":"10.1016\/j.pharep.2014.09.004_bib0320","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1471-4159.2008.05396.x","article-title":"Etazolate, a neuroprotective drug linking GABAA receptor pharmacology to amyloid precursor protein processing","volume":"106","author":"Marcade","year":"2008","journal-title":"J Neurochem"},{"issue":"9","key":"10.1016\/j.pharep.2014.09.004_bib0325","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2165\/00023210-200317090-00004","article-title":"The glutamatergic system and Alzheimer's disease","volume":"17","author":"Butterfield","year":"2003","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.pharep.2014.09.004_bib0330","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejphar.2012.07.032","article-title":"Memantine prevents cognitive impairment and reduces Bcl-2 and caspase 8 immunoreactivity in rats injected with amyloid \u03b2 1\u201340","volume":"692","author":"Miguel-Hidalgo","year":"2012","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"10.1016\/j.pharep.2014.09.004_bib0335","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/gps.2766","article-title":"Efficacy of memantine in delaying clinical worsening in Alzheimer's disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD","volume":"27","author":"Hellweg","year":"2012","journal-title":"Int J Geriatr Psychiatry"},{"issue":"3","key":"10.1016\/j.pharep.2014.09.004_bib0340","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3233\/JAD-2012-121447","article-title":"Modulation of \u03b17 nicotinic acetylcholine receptor and fibrillar amyloid-\u03b2 interactions in Alzheimer's disease brain","volume":"33","author":"Ni","year":"2013","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.pharep.2014.09.004_bib0345","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pneurobio.2012.06.010","article-title":"The serotonergic system in ageing and Alzheimer's disease","volume":"99","author":"Rodriguez","year":"2012","journal-title":"Prog Neurobiol"},{"issue":"9","key":"10.1016\/j.pharep.2014.09.004_bib0350","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.tips.2008.07.001","article-title":"A role for the 5-HT 1A, 5-HT 4 and 5-HT 6 receptors in learning and memory","volume":"29","author":"King","year":"2008","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"10.1016\/j.pharep.2014.09.004_bib0355","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1365-2125.2008.03348.x","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects","volume":"67","author":"Patat","year":"2009","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.pharep.2014.09.004_bib0360","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/gps.2562","article-title":"SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study","volume":"26","author":"Maher-Edwards","year":"2011","journal-title":"Int J Geriatr Psychiatry"},{"issue":"2","key":"10.1016\/j.pharep.2014.09.004_bib0365","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/FBP.0b013e328343d804","article-title":"Effects of 5-HT6 antagonists, Ro-4368554 and SB-258585, in tests used for the detection of cognitive enhancement and antipsychotic-like activity","volume":"22","author":"Gravius","year":"2011","journal-title":"Behav Pharmacol"},{"issue":"2","key":"10.1016\/j.pharep.2014.09.004_bib0370","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1124\/jpet.110.174458","article-title":"Activation of brain histaminergic neurotransmission: a mechanism for cognitive effects of memantine in Alzheimer's disease","volume":"336","author":"Motawaj","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.pharep.2014.09.004_bib0375","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1358\/dnp.2010.23.2.1475899","article-title":"Therapeutic potential of histamine H3 receptor antagonists in dementias","volume":"23","author":"Chazot","year":"2010","journal-title":"Drug News Perspect"},{"issue":"1","key":"10.1016\/j.pharep.2014.09.004_bib0380","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1124\/jpet.110.166876","article-title":"Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease","volume":"336","author":"Brioni","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.pharep.2014.09.004_bib0385","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1365-2125.2012.04472.x","article-title":"Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers","volume":"75","author":"Othman","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.pharep.2014.09.004_bib0390","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2174\/1567205011310030003","article-title":"The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H3 receptor antagonist in patients with mild to moderate Alzheimers disease: a preliminary investigation","volume":"10","author":"Nathan","year":"2013","journal-title":"Curr Alzheimer Res"},{"issue":"1","key":"10.1016\/j.pharep.2014.09.004_bib0395","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.expneurol.2006.08.008","article-title":"Caffeine and adenosine A 2a receptor antagonists prevent \u03b2-amyloid (25-35)-induced cognitive deficits in mice","volume":"203","author":"Dall\u2019Igna","year":"2007","journal-title":"Exp Neurol"},{"issue":"5","key":"10.1016\/j.pharep.2014.09.004_bib0400","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1046\/j.1365-2990.2002.00414.x","article-title":"The role of cytochrome c oxidase deficient hippocampal neurones in Alzheimer's disease","volume":"28","author":"Cottrell","year":"2002","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1","key":"10.1016\/j.pharep.2014.09.004_bib0405","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jns.2009.02.370","article-title":"Dendritic pathology in Alzheimer's disease","volume":"283","author":"Baloyannis","year":"2009","journal-title":"J Neurol Sci"},{"issue":"14","key":"10.1016\/j.pharep.2014.09.004_bib0410","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.addr.2009.07.016","article-title":"The failure of mitochondria leads to neurodegeneration: do mitochondria need a jump start?","volume":"61","author":"Lee","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.pharep.2014.09.004_bib0415","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/978-3-7091-7508-8_30","article-title":"Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study","volume":"54","author":"Gutzmann","year":"1998","journal-title":"J Neural Transm Suppl"},{"issue":"18","key":"10.1016\/j.pharep.2014.09.004_bib0420","doi-asserted-by":"crossref","first-page":"16504","DOI":"10.1074\/jbc.M110.208447","article-title":"Alternative mitochondrial electron transfer as a novel strategy for neuroprotection","volume":"286","author":"Wen","year":"2011","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.pharep.2014.09.004_bib0425","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/archneurol.2012.85","article-title":"Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures","volume":"69","author":"Galasko","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pharep.2014.09.004_bib0430","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3233\/JAD-2010-100564","article-title":"Mitochondria-targeted antioxidants protect against amyloid-\u03b2 toxicity in Alzheimer's disease neurons","volume":"20","author":"Manczak","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.pharep.2014.09.004_bib0435","first-page":"11","article-title":"Vitamin E for Alzheimer's dementia and mild cognitive impairment","author":"Farina","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.pharep.2014.09.004_bib0440","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jalz.2013.01.014","article-title":"Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data","volume":"10","author":"Dysken","year":"2014","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.pharep.2014.09.004_bib0445","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.neuroscience.2012.02.046","article-title":"Rutin prevents cognitive impairments by ameliorating oxidative stress and neuroinflammation in rat model of sporadic dementia of Alzheimer type","volume":"210","author":"Javed","year":"2012","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.pharep.2014.09.004_bib0450","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2174\/157015910792246209","article-title":"Clinical aspects of melatonin intervention in Alzheimer's disease progression","volume":"8","author":"Cardinali","year":"2010","journal-title":"Curr Neuropharmacol"},{"issue":"37","key":"10.1016\/j.pharep.2014.09.004_bib0455","doi-asserted-by":"crossref","first-page":"9287","DOI":"10.1523\/JNEUROSCI.3348-08.2008","article-title":"Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor \u03b3 agonist","volume":"28","author":"Nicolakakis","year":"2008","journal-title":"J Neurosci"},{"issue":"4","key":"10.1016\/j.pharep.2014.09.004_bib0460","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.3233\/JAD-2010-101332","article-title":"Secretase-independent and RhoGTPase\/PAK\/ERK-dependent regulation of cytoskeleton dynamics in astrocytes by NSAIDs and derivatives","volume":"22","author":"Lichtenstein","year":"2010","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.pharep.2014.09.004_bib0465","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/jnc.12059","article-title":"Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease","volume":"124","author":"Choi","year":"2013","journal-title":"J Neurochem"},{"issue":"6","key":"10.1016\/j.pharep.2014.09.004_bib0470","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/ana.21053","article-title":"Simvastatin enhances learning and memory independent of amyloid load in mice","volume":"60","author":"Li","year":"2006","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.pharep.2014.09.004_bib0475","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1111\/j.1471-4159.2004.02980.x","article-title":"Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones","volume":"92","author":"B\u00f6sel","year":"2005","journal-title":"J Neurochem"},{"issue":"2","key":"10.1016\/j.pharep.2014.09.004_bib0480","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.expneurol.2009.09.013","article-title":"Cholesterol and statins in Alzheimer's disease: current controversies","volume":"223","author":"Fonseca","year":"2010","journal-title":"Exp Neurol"},{"issue":"11\u201312","key":"10.1016\/j.pharep.2014.09.004_bib0485","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1089\/ars.2006.8.2047","article-title":"Reproductive hormones modulate oxidative stress in Alzheimer's disease","volume":"8","author":"Barron","year":"2006","journal-title":"Antioxid Redox Signal"},{"issue":"8","key":"10.1016\/j.pharep.2014.09.004_bib0490","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/j.1745-7254.2007.00618.x","article-title":"Effects of long-term, low-dose sex hormone replacement therapy on hippocampus and cognition of postmenopausal women of different apoE genotypes","volume":"28","author":"Yue","year":"2007","journal-title":"Acta Pharmacol Sin"},{"issue":"2","key":"10.1016\/j.pharep.2014.09.004_bib0495","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/archneur.63.2.nct50002","article-title":"Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men","volume":"63","author":"Lu","year":"2006","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.pharep.2014.09.004_bib0500","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2174\/156720512799015109","article-title":"The potential use of hormone-based therapeutics for the treatment of Alzheimer's disease","volume":"9","author":"Carroll","year":"2012","journal-title":"Curr Alzheimer Res"},{"issue":"1","key":"10.1016\/j.pharep.2014.09.004_bib0505","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00002093-200000001-00006","article-title":"Nerve growth factor treatment in dementia","volume":"14","author":"J\u00f6nhagen","year":"2000","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.pharep.2014.09.004_bib0510","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1358\/dot.2012.48(Suppl.A).1739721","article-title":"Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia","volume":"48","author":"Allegri","year":"2012","journal-title":"Drugs Today (Barc)"},{"issue":"6","key":"10.1016\/j.pharep.2014.09.004_bib0515","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s10522-008-9162-6","article-title":"Early-life events may trigger biochemical pathways for Alzheimer's disease: the \u201cLEARn\u201d model","volume":"9","author":"Lahiri","year":"2008","journal-title":"Biogerontology"},{"issue":"10","key":"10.1016\/j.pharep.2014.09.004_bib0520","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s12603-009-0249-9","article-title":"Dietary folate, vitamin B-12, vitamin B-6 and incident Alzheimer's disease: the cache county memory, health, and aging study","volume":"13","author":"Nelson","year":"2009","journal-title":"J Nutr Health Aging"},{"issue":"7232","key":"10.1016\/j.pharep.2014.09.004_bib0525","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/nature07767","article-title":"APP binds DR6 to trigger axon pruning and neuron death via distinct caspases","volume":"457","author":"Nikolaev","year":"2009","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.pharep.2014.09.004_bib0530","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.neuropharm.2007.07.015","article-title":"A selective, non-peptide caspase-1 inhibitor, VRT-018858, markedly reduces brain damage induced by transient ischemia in the rat","volume":"53","author":"Ross","year":"2007","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pharep.2014.09.004_bib0535","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pnpbp.2005.06.013","article-title":"Effects of selective neuronal nitric oxide synthase inhibition on sleep and wakefulness in the rat","volume":"30","author":"Cavas","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"2","key":"10.1016\/j.pharep.2014.09.004_bib0540","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/35055104","article-title":"Protein S-nitrosylation: a physiological signal for neuronal nitric oxide","volume":"3","author":"Jaffrey","year":"2001","journal-title":"Nat Cell Biol"},{"issue":"6","key":"10.1016\/j.pharep.2014.09.004_bib0545","doi-asserted-by":"crossref","first-page":"453","DOI":"10.4161\/hv.4.6.6200","article-title":"Molecular and cellular mechanisms of DNA vaccines","volume":"4","author":"Coban","year":"2008","journal-title":"Hum Vaccin"},{"issue":"32","key":"10.1016\/j.pharep.2014.09.004_bib0550","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.2174\/092986711797535245","article-title":"Multi-target-directed ligands in Alzheimer's disease treatment","volume":"18","author":"Bajda","year":"2011","journal-title":"Curr Med Chem"},{"issue":"12","key":"10.1016\/j.pharep.2014.09.004_bib0555","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1096\/fj.05-4910fje","article-title":"A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing","volume":"20","author":"Yogev-Falach","year":"2006","journal-title":"FASEB J"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114014002886?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114014002886?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:35:44Z","timestamp":1752611744000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2014.09.004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":111,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S1734114014002886"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2014.09.004","relation":{},"ISSN":["1734-1140"],"issn-type":[{"value":"1734-1140","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review on Alzheimer's disease pathophysiology and its management: an update","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2014.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.","name":"copyright","label":"Copyright"}]}}